Free from Publisher

Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants

A Addetia, L Piccoli, JB Case, YJ Park, M Beltramello… - Biorxiv, 2023 - biorxiv.org
Currently circulating SARS-CoV-2 variants acquired convergent mutations at receptor-
binding domain (RBD) hot spots. Their impact on viral infection, transmission, and efficacy of …
被引用次数：22 相关文章

Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants

A Addetia, L Piccoli, JB Case… - … : the preprint server …, 2023 - pubmed.ncbi.nlm.nih.gov
Currently circulating SARS-CoV-2 variants acquired convergent mutations at receptor-
binding domain (RBD) hot spots. Their impact on viral infection, transmission, and efficacy of …

Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants.

A Addetia, L Piccoli, JB Case, YJ Park… - Biorxiv: the Preprint …, 2023 - europepmc.org
Currently circulating SARS-CoV-2 variants acquired convergent mutations at receptor-
binding domain (RBD) hot spots 1. Their impact on viral infection, transmission, and efficacy …

Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants

A Addetia, L Piccoli, JB Case, YJ Park, M Beltramello… - bioRxiv - ncbi.nlm.nih.gov
Currently circulating SARS-CoV-2 variants acquired convergent mutations at receptor-
binding domain (RBD) hot spots. Their impact on viral infection, transmission, and efficacy of …

Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants

A Addetia, L Piccoli, JB Case, YJ Park, M Beltramello… - bioRxiv, 2023 - biorxiv.org
Currently circulating SARS-CoV-2 variants acquired convergent mutations at receptor-
binding domain (RBD) hot spots 1. Their impact on viral infection, transmission, and efficacy …